A Phase 2 interventional study of deoxycytidine and deoxythymidine in Mitochondrial Diseases, Mitochondrial Encephalomyopathy and Mitochondrial Encephalopathy, sponsored by Kenneth Myers, MD. Recruiting at 1 site in Canada. Open to participants aged 1 Month to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Kenneth Myers, MD · Phase 2, Interventional, and Treatment
Wang J, El-Hattab AW, Wong LJC. TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form. 2012 Dec 6 [updated 2018 Jul 26]. In: Adam MP, Bick S, Mirzaa…PubMed 23230576 ↗. 1 publication citing this study linked from PubMed
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Mitochondrial Diseases with a site in Canada — 3 open to participants now, 3 under way, 1 of them phase 3. Mitochondrial Diseases · Canada.
Among the 10 studies in Mitochondrial Diseases with a site in Canada, this one is the only one that started in 2021, is the only one in phase 2, and was the 9th registered.
189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.
Browse Mitochondrial Diseases studies →3 of the 10 studies in Mitochondrial Diseases with a site in Canada are open now. Recruiting first, the newest first:
Columbia University · Sites in Canada, United States
Healthy volunteers
Kenneth Myers, MD · Sites in Canada
Ages 6–60
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.
This study: 1 Month to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 35 across 114 interventional studies indexed under Mitochondrial Diseases.
Median enrollment 68 across the 7 interventional studies, 90 across the 3 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
Kenneth Myers, MD is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Kenneth Myers, MD has 2 studies filed under Mitochondrial Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Mitochondrial Diseases with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Mitochondrial Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mitochondrial DNA (mtDNA) depletion syndromes (MDS) are a genetically and clinically heterogeneous group of autosomal recessive disorders that are characterized by a severe reduction in mtDNA content leading to impaired energy production in affected tissues and organs. MDS are due to defects in mtDNA maintenance caused by mutations in nuclear genes that function in either mitochondrial nucleotide synthesis. MDS are phenotypically heterogeneous and usually classified as myopathic, encephalomyopathic, hepatocerebral or neurogastrointestinal.
No efficacious therapy is available for any of these disorders. Affected individuals should have a comprehensive evaluation to assess the degree of involvement of different systems. Treatment is directed mainly toward providing symptomatic management. No treatment for MDS.
Clinical trials studies and in vitro/in vivo research studies showed that the enhancement of the salvage pathway by increasing the availability of deoxyribonucleosides needed for each specific genetic defect prevents mtDNA depletion.
Early recognition and immediate therapy to restore mitochondrial function could potentially improve clinical course.
Confirming the benefit of deoxynucleosides as a safe and potentially efficacious therapy, will lead to the availability of the first specific and effective treatment for Mitochondria Depletion Disorders.
In this phase II Trial a mix of Deoxynucleosides Pyrimidine (Deoxycytidine dC and Deoxythymidine dT) will be used as early treatment of MDS.
The dose used has been already used in other clinical trials, and appears to effective and well-tolerated. The subjects included are children (0-18Y), with positive MDS diagnosis and express mutations in one of the following genes: POLG, POLG2, C10orf2, RRM2B, MPV17, SUCLA2, SUCLG1, FBXL4, DTYMK. Subjects with MDS expressing neurological phenotypes dysfunction.
This Trial is designed as Phase II, Monocenter, Open label study in the pediatric population.
The aim is to evaluate the safety, tolerability and efficacy of Deoxycytidine and Deoxythymidine in treatment of children with Mitochondrial Depletion Disorders.
Primary Objectives The primary objective of this study is to evaluate the efficacy of dC/dT100-400 in subjects with mitochondria depletion disorders.
Secondary Objectives The secondary objectives of this study are to evaluate tolerability and safety of dC/dT100-400 in subjects with mitochondria depletion disorders.
Efficacy of dC/dT100-400 :
First Outcomes:
Secondary Outcomes:
Safety and tolerability will be tested by recording adverse effects (AE): AE will be monitored and collected throughout the study.
Bloodwork for different assessments:
Complete blood and platelet counts (CBC) will be performed to monitor any potential toxicity, liver function (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), bilirubin and albumin.), kidney function (creatinine, urea, electrolytes). Assess for myopathy with serum creatine kinase (CK).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Negative urinary pregnancy test at screening Agree to use effective for the duration of the study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children \& Adult (0-60 Y), who takes the investigational product deoxynucleosides pyrimidine (mix of deoxycytidine and deoxythymidine), following the protocol.
Combination Product: deoxycytidine and deoxythymidine
Drug pages: DeoxycytidineStudies of DeoxycytidineDeoxycytidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ThymidineStudies of ThymidineThymidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over trid or bid for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 1825. Doses was chosen according to the safety and efficacy doses used in the literature.
Rate of Responder versus Non-Responder Status with investigational product
There is no estimation of sample size, the number will depend on subjects enrolled. We assume we can include about 50 to 100 subjects with mitochondrial depletion disorder. This study is designed as Phase II trial case series, the data will be presented graphically The IP of study will be considered positive if more than 2 responders are observed in 5 subjects. This design yields a marginal one-sided type I error rate (α) of 5% and power of 80%. For more than one participant engages in a study, the spaghetti plot showing all of their data in the same figure will be used as tool for visualization. Visual analysis of graphed data has been the traditional method for evaluating treatment effects in series cases research.
Time frame: 260 weeks
Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs)
"Responder" defined as having ≥ 2 of (1) electroencephalography EEG improvement, (2) decreased seizure frequency, (3) cognitive improvement, (4) caregiver impression of improvement, (5) clinical improvement, (6) Safety profile will be assessed through number of participants experiencing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, and physical examinations.
Time frame: 260 weeks
Plan to share: Yes — REDCap software will be used as IPD. The data's will be shared anonymous, subject will bes identified by an Identifiant (ID). REDCap is managed by quality data's teams of research institute of McGill University Health Center (RI-MUHC). For clinical study reports since the study is planned at the Children Hospital of Montreal, Clinical Study Report (CSR) access will be done through open architecture clinical information system (Oacis) tool of hospital Study Protocol And Informed Consent Form (ICF) will be shared by Email or on core network of RIMUHC
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 104 weeks
Access criteria: Research Staff, Principal Investigator (PI), Co-Investigator, regulation authority and clinical research associate (CRA) for monitoring are authorized to access to the data's for CRA (anonymous data's)
Started Oct 2021 (actual). Primary completion is estimated for Jun 2029, 92 months after the start.
Of 16 phase 2 interventional studies under Mitochondrial Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 85. This study's planned 92 months is above that.
How these figures are worked out, and which studies are left out of them.
Wang J, El-Hattab AW, Wong LJC. TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form. 2012 Dec 6 [updated 2018 Jul 26]. In: Adam MP, Bick S, Mirzaa…PubMed 23230576 ↗. 1 publication citing this study linked from PubMed
Wang J, El-Hattab AW, Wong LJC. TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form. 2012 Dec 6 [updated 2018 Jul 26]. In: Adam MP, Bick S, Mirzaa…PubMed 23230576 ↗. 1 publication citing this study linked from PubMed
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deoxycytidine · Thymidine
Kenneth Myers, MD